Rxilient's Oncology strategy focuses on meeting the unmet needs of the Southeast Asian market with innovative therapies and ready access. We believe that everyone should be able to afford quality care during their cancer journey.

Our focus priorities:

Working with efficacious medication backed by robust clinical research
Streamlining medicine production and logistics.


Transarterial Chemoembolization (TACE) has been a mainstay in the treatment of liver cancer. EmboLogĀ® S is a degradable starch microsphere indicated for use in TACE.

Published papers

for the use of Degradable Starch Microspheres manufactured by Serumwerk Bernburg AG.